Neurophet Introduces Advanced Brain Imaging Solutions at AAIC 2026

Neurophet Showcases Advanced Solutions at AAIC 2026

Neurophet, a pioneering company in artificial intelligence (AI) solutions for brain disorder diagnoses and treatments, is set to make waves at the Alzheimer’s Association International Conference (AAIC) 2026 in London, United Kingdom, from July 12 to 15. Co-CEOs Jake Junkil Been and Donghyeon Kim are leading the company’s display of cutting-edge technology aimed at improving patient outcomes in Alzheimer's disease management.

Showcasing Neurophet AQUA AD Plus

During this prestigious conference, Neurophet will unveil its latest brain imaging analysis tool, Neurophet AQUA AD Plus. This comprehensive solution enhances the prescription and evaluation process for Alzheimer’s disease therapies by providing quantitative analyses of both MRI (Magnetic Resonance Imaging) and PET (Positron Emission Tomography) scans.

The Neurophet AQUA AD Plus contributes significantly throughout the treatment journey. It assists medical professionals in determining patient eligibility prior to treatment, monitors any adverse effects during therapy, and evaluates treatment outcomes post-administration. The objective is not just to support doctors but also to improve the patient experience and enhance overall treatment efficacy.

In addition to Neurophet AQUA AD Plus, the company will present Neurophet AQUA, its software solution dedicated to neurodegeneration imaging analysis, and Neurophet SCALE PET, which focuses on quantitative PET image analysis. Neurophet's participation in AAIC 2026 underscores its commitment to innovation and its intent to forge partnerships with pharmaceutical companies and clinical research organizations (CROs).

Expanding Global Partnerships

Jake Junkil Been, Co-CEO of Neurophet, noted the increasing demand for their solutions among healthcare institutions in Korea and globally. Through AAIC 2026, the company aims to accelerate the establishment of strategic partnerships within the imaging biomarker analysis sector. These partnerships are vital for enhancing the quality of clinical trials focused on Alzheimer’s and Parkinson’s disease therapies.

At the conference, Neurophet will engage in discussions with major pharmaceutical and biotechnology companies, as part of its initiative to expand its business network and collaborate on advancements in medical imaging technologies.

Importance of AAIC 2026

The Alzheimer’s Association International Conference is renowned as the world’s most significant event dedicated to dementia and Alzheimer’s disease. It serves as a global platform for experts, researchers, and industry professionals to exchange the latest insights and advancements in the field. The conference does not only facilitate academic discourse but also fosters partnerships that can lead to groundbreaking developments in treatment and patient care.

About Neurophet

Founded in 2016, Neurophet specializes in creating AI-based solutions that aid in diagnosing and treating brain disorders. Its innovative product lineup includes: Neurophet AQUA for brain MRI analysis, Neurophet SCALE PET, focused on PET image quantitative analysis, and software dedicated to treatment planning for brain stimulation therapies. Neurophet’s commitment is clear: leveraging AI to revolutionize how brain disorders are diagnosed and treated, thereby improving overall patient care.

Through their cutting-edge solutions, Neurophet stands at the forefront of a rapidly evolving medical landscape, addressing critical healthcare needs with advanced technology. As they prepare to participate in AAIC 2026, the company is poised not just to showcase their innovations but also to forge vital connections that will help shape the future of brain health.